JGC
PCRX icon

J. Goldman & Co’s Pacira BioSciences PCRX Stock Holding History

J. Goldman & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-245,000
Closed -$9.2M – 413
2017
Q3 		$9.2M Buy
+245,000
New +$9.86M 0.46% 62

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's PCRX Position: Q1 2026 in Review

J. Goldman & Co reduced its Pacira BioSciences (PCRX) stake by 78% in Q1 2026, selling an estimated $7.54M and leaving 97,772 shares worth $2.21M. The position accounts for 0.06% of the portfolio, ranked #307.

J. Goldman & Co first reported a position in PCRX in Q3 2017 and has held it in 11 quarters since. The position peaked at $21.3M in Q1 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • J. Goldman & Co held 97,772 shares of Pacira BioSciences worth $2.21M as of Q1 2026.
  • J. Goldman & Co sold 339,481 Pacira BioSciences shares in Q1 2026, an estimated $7.54M.
  • Pacira BioSciences made up 0.06% of J. Goldman & Co's portfolio in Q1 2026, its #307 holding.
  • J. Goldman & Co first reported a position in Pacira BioSciences in Q3 2017 and has held it in 11 quarters since.
  • J. Goldman & Co's Pacira BioSciences position peaked at $21.3M in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.